SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/09/20 Marinus Pharmaceuticals Inc S-3 7:1.6M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: S-3 Registration Statement for Securities Offered HTML 376K Pursuant to a Transaction 2: EX-1.1 Underwriting Agreement HTML 149K 3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 230K 4: EX-4.4 Instrument Defining the Rights of Security Holders HTML 231K 5: EX-5.1 Opinion of Counsel re: Legality HTML 21K 6: EX-5.2 Opinion of Counsel re: Legality HTML 11K 7: EX-23.3 Consent of Experts or Counsel HTML 7K
tm2024336-1_s3 - none - 3.904047s |
|
Delaware
|
| |
20-0198082
|
|
|
(State or other jurisdiction of incorporation or
organization) |
| |
(I.R.S. Employer Identification No.)
|
|
|
Steven J. Abrams
Hogan Lovells US LLP 1735 Market Street, 23rd Floor Philadelphia, PA 19103 (267) 675-4600 |
| |
Martha Manning
Vice President, General Counsel and Secretary Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd. Radnor, Pennsylvania 19087 (484) 801-4670 |
|
| Large accelerated filer ☐ | | | Accelerated filer ☒ | | | Non-accelerated filer ☐ | | | Smaller reporting company ☒ | |
| | | | | | | | | | Emerging growth company ☐ | |
| | ||||||||||||||||||||||||||||
Title of each class of securities to be registered
|
| | |
Amount to be
registered |
| | |
Proposed
maximum offering price per unit |
| | |
Proposed
maximum aggregate offering price |
| | |
Amount of
registration fee |
| ||||||||||||
Common stock, $0.001 per share
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | |
|
(2)
|
| | | | |
|
(3)
|
| |
Preferred stock, $0.001 par value
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | |
|
(2)
|
| | | | |
|
(3)
|
| |
Debt securities
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | |
|
(2)
|
| | | | |
|
(3)
|
| |
Warrants
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | |
|
(2)
|
| | | | |
|
(3)
|
| |
Units
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | |
|
(2)
|
| | | | |
|
(3)
|
| |
Total
|
| | | |
|
(1)
|
| | | | |
|
(2)
|
| | | | | $ | 250,000,000 | | | | | | $ | 25,883(3) | | |
Item
|
| |
Page
Number |
| |||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| | ||
| | |
|
| |
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-3 | | | |
| | | | | S-4 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-10 | | | |
| | | | | S-12 | | | |
| | | | | S-13 | | | |
| | | | | S-14 | | | |
| | | | | S-14 | | | |
| | | | | S-15 | | | |
| | | | | S-15 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 2.53 | | |
|
Net tangible book value per share as of March 31, 2020
|
| | | $ | 0.50 | | | | | | | | |
|
Increase in pro forma tangible book value per share attributable to June 2020 public offering and the conversion of Series A Preferred Stock
|
| | | $ | 0.21 | | | | | | | | |
|
Pro forma net tangible book value per share as of March 31, 2020
|
| | | $ | 0.71 | | | | | | | | |
|
Increase in pro forma net tangible book value per share after this offering
|
| | | $ | 0.29 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share as of March 31, 2020, after giving effect to this offering
|
| | | | | | | | | $ | 1.00 | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | 1.53 | | |
|
SEC registration fee
|
| | | $ | 25,883 | | |
|
FINRA filing fee
|
| | | | 38,000 | | |
|
Printing expenses
|
| | |
|
(1)
|
| |
|
Legal and accounting expenses
|
| | |
|
(1)
|
| |
|
Miscellaneous
|
| | |
|
(1)
|
| |
|
TOTAL
|
| | | $ | (1) | | |
| | | | MARINUS PHARMACEUTICALS, INC. | | |||
| | | | By: | | | /s/ Scott Braunstein, M.D. | |
| | | | | | |
Scott Braunstein, M.D.
President and Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
|
| |
President, Chief Executive Officer and Director
(Principal Executive Officer) |
| | | |
|
/s/ Edward F. Smith
|
| |
Vice President, Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer) |
| | | |
|
/s/ Nicole Vitullo
|
| |
Chairman of the Board and Director
|
| | | |
|
|
| |
Director
|
| | | |
|
|
| |
Director
|
| | | |
|
/s/ Elan Ezickson
|
| |
Director
|
| | | |
|
|
| |
Director
|
| | | |
|
|
| |
Director
|
| | |
This ‘S-3’ Filing | Date | Other Filings | ||
---|---|---|---|---|
12/1/20 | ||||
Filed on: | 7/9/20 | |||
7/8/20 | ||||
3/31/20 | 10-Q, 8-K, DEF 14A, PRE 14A | |||
12/31/19 | 10-K | |||
12/12/19 | 424B5, 8-K | |||
12/31/18 | 10-K | |||
12/1/17 | EFFECT | |||
10/31/17 | 10-Q, 8-K, S-3 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/24 Marinus Pharmaceuticals, Inc. 10-K 12/31/23 79:10M Toppan Merrill Bridge/FA 3/31/23 Marinus Pharmaceuticals, Inc. S-3 8:1.6M Toppan Merrill/FA 3/09/23 Marinus Pharmaceuticals, Inc. 10-K 12/31/22 73:10M Toppan Merrill Bridge/FA 3/24/22 Marinus Pharmaceuticals, Inc. 10-K 12/31/21 71:8.5M Toppan Merrill Bridge/FA 3/09/21 Marinus Pharmaceuticals, Inc. 10-K 12/31/20 65:7.6M Toppan Merrill Bridge/FA 8/06/20 Marinus Pharmaceuticals, Inc. 10-Q 6/30/20 42:4.1M Toppan Merrill Bridge/FA 7/16/20 SEC UPLOAD¶ 8/25/20 2:39K Marinus Pharmaceuticals, Inc. |